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Oxaliplatin use in palliative and adjuvant treatment of colon cancer is frequently limited by cumulative neurotoxicity, leading to
reduced quality of life and decreased dose. The mechanism of this neurotoxicity is unclear, but may relate to neuronal voltage-
gated sodium channels involving calcium chelation by a metabolite of the drug. Various preventative measures have been tested to
reducetheincidenceofneurotoxicity,includingcalciumandmagnesiuminfusions,doseinterruptionofthedrug,andprophylactic
neuromodulatory agents. Despite the promising eﬃcacy of these measures, they are not universally accepted. Less is known about
the best way to treat established neurotoxicity, which is permanent in some patients, although venlafaxine has shown promise
in small clinical trials. This paper analyzes the extent, cause and risk factors for neuropathy, and the potential preventative and
therapeutic treatments for oxaliplatin-induced neuropathy.
1.Introduction
Oxaliplatin is a 3rd-generation platinum-based chemother-
apeutic, possessing the 1,2 diaminocyclohexane-containing
carrier ligand, useful in treating advanced colorectal cancer.
It is often used in combination regimens with 5-ﬂourouracil
[1], capecitabine [2], or 5-ﬂourouracil/irinotecan [3] for the
treatment of colorectal cancer. Oxaliplatin has also been
studiedinclinicaltrialsforthetreatmentofothercancersbut
has found the most success in gastrointestinal neoplasms in-
cluding gastric, esophageal, and pancreatic cancers [4]. Plati-
num-basedchemotherapeuticshaveeﬀectviacellphasenon-
speciﬁc mechanisms causing the formation of cross-linking
DNA adducts, leading to strand breaks and inhibition of
DNA replication [5].
Oxaliplatin produces common side eﬀects of cytopenias,
peripheral neuropathy, diarrhea, and nausea [4]. Oxalipla-
tin-induced neurotoxicity (OXIN) is a recognized dose-lim-
iting complication [6]. This paper analyzes the extent, cause
and risk factors for neuropathy, and the potential preventa-
tive and therapeutic treatments for OXIN.
2. Extentof Problem
OXIN demonstrates two clinically signiﬁcant types: acute
and chronic. Neither type has its mechanism of action fully
elucidated. Acute OXIN usually begins with paresthesias and
dysesthesias of the hands and feet, but may include the
mouthorthroat[7].Itsonsetmaybeginduringtheinitialin-
fusion or up to 1-2 days following the administered dose and
is often triggered by cold. Typically, the symptoms will resol-
ve spontaneously within days, but often return upon subseq-
uent oxaliplatin administration. It is associated with addi-
tional symptoms of muscular hyperactivity including jaw
tightness, cramps, and fasciculations [8]. The proposed
mechanism of action of acute OXIN includes altering the
current of voltage-gated Na(+) channels in response to oxa-
late, a metabolic by-product of oxaliplatin [9, 10]. In addi-
tion, oxalate may interact indirectly with the voltage-gated
Na(+) channels through chelation of calcium (Ca) and mag-
nesium (Mg) [11].
Chronic OXIN, in contrast, is thought to be caused by
a dose-dependent accumulation of platinum compounds in
the dorsal root ganglia, causing neuronal atrophy and apop-
tosis. It is primarily a sensory neuropathy aﬀecting the extre-
mities and develops based upon the total cumulative dose of
oxaliplatin [12].
There is a wide discrepancy in the literature on how to
measure and grade OXIN. The Common Terminology Cri-
teria for Adverse Events (CTCAE) is often used by clinicians
to score and monitor OXIN. The grading of peripheral2 Journal of Oncology
Table 1: Common terminology criteria for adverse events version 4.03.
Adverse event Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
Dysesthesia Mild sensory alteration
Moderate sensory
alteration; limiting
instrumental ADL
Severe sensory alteration;
limiting self-care ADL ——
Paresthesia Mild symptoms
Moderate symptoms;
limiting instrumental
ADL
Severe symptoms;
limiting self care ADL ——
Peripheral
sensory
neuropathy
Asymptomatic; loss of
deep tendon reﬂexes or
paresthesia
Moderate symptoms;
limiting instrumental
ADL
Severe symptoms;
limiting self care ADL
Life-threatening
consequences; urgent
intervention indicated
Death
Peripheral
motor
neuropathy
Asymptomatic; clinical
or diagnostic
observations only;
intervention not
indicated
Moderate symptoms;
limiting instrumental
ADL
Severe symptoms;
limiting self care ADL;
assistive device indicated
Life-threatening
consequences; urgent
intervention indicated
Death
neuropathy from the CTCAE version 4.0 [13] is shown in
Table 1. Other rating systems include the Total Neuropathy
Score (TNS) [14], the Eastern Cooperative Oncology Group
(ECOG) toxicity criteria, the oxaliplatin-speciﬁc scale [12],
and criteria from individual studies or the World Health
Organization [8]. Of these systems, none have been validated
for oxaliplatin toxicity scoring. The CTCAE and the ECOG
criteria have beencomparedto theTNSwithreasonablevali-
dityforallchemotherapeutics[15].Mostclinicaltrialsstudy-
ing oxaliplatin use the CTCAE or the WHO criteria [2, 16,
17].
3. IncidenceofOxaliplatin-InducedNeuropathy
G r a d e2o rw o r s en e u r o p a t h yo c c u r si na p p r o x i m a t e l y
40–50%ofpatientsreceivingoxaliplatin,withgrade3neuro-
pathy occurring in 10–20% of patients [1, 18–20]. The
majority of patients have improvement of their symptoms,
but there is still a signiﬁcant proportion of patients left with
some symptoms more than 2 years after completing therapy
[1, 20, 21]. In the MOSAIC trial, 44% of patients had grade 2
or grade 3 neurotoxicity at the end of treatment, 6% one year
aftertherapy,and4%after18months[1].InaEuropeantrial
ofoxaliplatin,26%ofpatientswithgrade3neurotoxicityhad
persistent symptoms after a median followup of 28 months
[20].Morethan10%ofpatientsintheNSABPC-07trialwho
received oxaliplatin had persistent neurological symptoms 2
years after completing therapy [21]. In a small, 25-patient
prospective study speciﬁcally evaluating the development of
OXIN, 56% of patients developed grade 1-2 OXIN and 8%
developed grade 3 OXIN based on a modiﬁed TNS scoring
[22]. An Australian prospective study of OXIN reported that
neuropathy of any grade persisted in 79% of patients, and
grade 3 neuropathy persisted in 12% of patients after a med-
ian followup of 29 months [23].
3.1. Risk Factors. Preexistent symptomatic peripheral neuro-
pathy has served as exclusion criteria from trials of oxali-
platin, and data on exacerbation of underlying neurotoxicity
by oxaliplatin is limited. However, diabetes mellitus, which
carriesahighsusceptibilityofperipheralsensoryneuropathy,
does not appear to be associated with increased risk of de-
velopingOXIN[24].Agealsohasnotbeenshowntobearisk
factor for the development of OXIN [25]. It has been hypo-
thesized that genetic diﬀerences in the glutathione transfer-
ase pathway may lead to higher rates of neurotoxicity, per-
haps due to a decreased ability to respond to oxaliplatin-in-
duced oxidative stress [26–28]. However there is conﬂicting
evidence whether 105Val polymorphisms of glutathione S-
transferase (GSTP1) leads to higher rates of OXIN [29, 30]
and there are currently no clinical applications of this basic
scientiﬁc work. Integrin beta-3 polymorphisms have been
shown to be unrelated to the development of OXIN, but may
be related to its severity [31]. In a genome-wide analysis of
96 colon cancer patients, a group from South Korea showed
a possible connection between OXIN and the DDX18 and
NRP2genes,althoughtheputativemechanismofinteraction
of these in relation to OXIN is uncertain [32].
3.2. Prophylaxis. Two diﬀerent strategies have been advocat-
ed to prevent OXIN: (1) a stop-and-go approach with inter-
mittent oxaliplatin dosing and (2) the concurrent use of neu-
romodulatory agents which include antidepressants, anti-
epileptics, or calcium and magnesium infusions.
3.2.1. Stop-and-Go Strategy. Given the reversibility of OXIN
in the majority of patients, two separate trials have evaluat-
ed stopping oxaliplatin after 6 cycles of therapy, and reintro-
ducingtheoxaliplatinafterapredeﬁnedbreakwhilecontinu-
ing the 5FU backbone of chemotherapy [33–35]. The
OPTIMOX1trialwasaEuropeantrialinvolving620patients,
which compared continuous FOLFOX-4 regimen (oxalipla-
tin 85mg/m2) to an intermittent FOLFOX-7 regimen (oxali-
platin 130mg/m2 for 6 cycles with infusional 5FU/LV then
a complete oxaliplatin treatment break) with maintenance
5FU/LV (12 cycles) followed by reintroduction of FOLFOX-
7 (6 cycles) [33]. The incidence of neuropathy was less in the
intermittent arm between cycle 7 and 18, but the overall rate
of grade 3 neurotoxicity was not signiﬁcantly diﬀerent (13%
intermittent FOLFOX-7 versus 19% FOLFOX-4, P = 0.12).Journal of Oncology 3
Notably, although 60% of patients in the intermittent arm
did not receive further oxaliplatin after their scheduled break
from treatment, the response rate, progression-free survi-
val,andoverallsurvivalweresimilarinbotharms.TheCON-
cePT trial also compared intermittent to continuous oxali-
platinadministration,ina2×2designadditionallyrandomi-
zingpatientstoeithercalcium/magnesiuminfusionorplace-
bo [35]. This trial used modiﬁed FOLFOX-7 (oxaliplatin
85mg/m2)andbevacizumabinbotharms,butwithalternat-
ing blocks of 8 cycles of treatment with oxaliplatin with 8
cycles of biweekly 5FU/LV/bevacizumab in the intermittent
treatment arm. Grade 3 neurotoxicity was signiﬁcantly re-
duced in the intermittent oxaliplatin arm versus the contin-
uous oxaliplatin arm (10% versus 24%). Dose delay or dose
reduction was signiﬁcantly less in the intermittent arm com-
pared to the continuous arm (8% versus 22%). Additionally,
the intermittent oxaliplatin arm had better time to treatment
failure and progression-free survival than the continuous
arm.
While the improvement in neurotoxicity is appealing in
the stop-and-go approach use of oxaliplatin, the continua-
tion of the 5FU/LV may be important to maintain eﬃcacy
relative to continuous oxaliplatin [36]. The OPTIMOX2 trial
compared chemotherapy discontinuation after 6 cycles of
FOLFOX-7 with maintenance therapy after 6 cycles of
FOLFOX-7, as was used in OPTIMOX1. This approach re-
sulted in inferior duration of disease control and inferior
survival,andisnotrecommended[37].However,itisimpor-
tant to note that this study was terminated early (and thus
analyzed as a randomized phase II), and tumor size was
required to surpass baseline measurements prior to reintro-
duction—an approach which is not used commonly in the
clinic. The MACRO trial was a large randomized phase III
study that evaluated capecitabine and oxaliplatin (XELOX)
with bevacizumab for 6 cycles, followed by maintenance
XELOX-bevacizumab or single-agent bevacizumab [38].
This study reported a reduction in grade 3/4 neuropathy
from 24% in the continuous XELOX-bevacizumab arm to
7% in the bevacizumab alone arm, with no diﬀerence in PFS,
OS between the two arms. Therefore stop-and-go oxaliplatin
u s ei sa se ﬃcacious as continuous oxaliplatin usage when
either a 5FU/LV or bevacizumab backbone is used as main-
tenance, and results in reduced neurotoxicity. The timing for
reintroduction of oxaliplatin is uncertain, and the optimum
oxaliplatin-based regimen to use with this approach is also
unknown.
3.2.2.CalciumandMagnesium. Calciumandmagnesiumin-
fusions have been tried as prophylactic therapy for OXIN, on
the basis that they may bind to oxalate, and reduce its eﬀect
on voltage-gated sodium channels [10, 39]. An encouraging
retrospective review [40] of a single institution experience
with calcium and magnesium infusions, given before and
after oxaliplatin administration, has led to three prospective
randomized trials of the strategy. Patients in the CONcePT
trial were randomized to either placebo, or Ca/Mg infusion
(calcium gluconate 1g, magnesium sulfate 1g, in 100mL of
5% dextrose in water, half an hour prior and half an hour
after oxaliplatin administration). Interim analysis of the
study data which suggested a decreased response rate in the
Ca/Mg arm led to premature closure of the trial [34]a f t e r
enrolment of only 139 patients. However a subsequent inde-
pendent review demonstrated that there was no signiﬁcant
diﬀerence in response rate or time to treatment failure bet-
weenthegroups.Ca/Mginfusiondidnotleadtoasigniﬁcant
reduction in grade 3/4 neurotoxicity either in the continuous
oxaliplatin arm (23% Ca/Mg group versus 24% placebo) or
in the intermittent arm (11% Ca/Mg group versus 8% place-
bo). There was also no diﬀerence in the groups between de-
lays and dose reductions. A retrospective review of the eﬀect-
iveness of Ca/Mg infusions on neuropathy from the CAIRO2
trial also reported no substantial beneﬁt in the reduction of
grade 3/4 neuropathy [41].
Incontrastthedoubleblinded,placebo-controlledN04C7
trial of patients receiving continuous FOLFOX reported sig-
niﬁcantly lower grade 2 or worse neurotoxicity in the Ca/Mg
arm (22% versus 41%) [18]. In addition, the Ca/Mg group
had decreased amounts of muscle cramping, but there was
no diﬀerence in cold sensitivity. The trial was unfortunately
closed after only 102 patients were recruited due to concerns
regarding the CONcePT trial’s early erroneous assessment of
inferior response in the Ca/Mg arm, leading to lack of statis-
tical power to determine if there was a diﬀerence in dose de-
lay and dose reduction between the two groups. Preliminary
data, taken from an early interim analysis of 52 patients on
the blinded, placebo-controlled Neuroxa trial, is also sup-
portive of Ca/Mg infusions [42]. There was a signiﬁcantly
lower frequency of grade 3/4 neurotoxicity in the group re-
ceiving Ca/Mg infusions (5% versus 24%), and there was no
diﬀerence in eﬃcacy between the groups.
An explanation for the possible discrepancy between the
insigniﬁcant outcomes of Ca/Mg in CONcePT and CAIRO2
compared to the beneﬁt seen in the N04C7 and NEUROXA
trial is the number of initial oxaliplatin cycles patients receiv-
ed. Half the patients in the CONcePT trial received stop-
and-go therapy with oxaliplatin, and all patients in CAIRO2
had at most 6 cycles of oxaliplatin. These measures by them-
selves have been shown to reduce neurotoxicity, as demon-
strated by the OPTIMOX1 trial [33]. In contrast the N04C7
and Neuroxa trial treated patients with continuous oxalipla-
tin, suggesting the beneﬁt of Ca/Mg infusions are limited to
this treatment strategy. However despite the favorable results
from the N04C7 and the NEUROXA trial, there are no cur-
rent data available on the eﬀect of Ca/Mg infusions on long-
er-term OXIN [53], and a subsequent further randomized
NCCTG trial has begun enrollment to answer this question.
3.2.3. Pharmacological Approaches. A variety of pharmacolo-
gical approaches to prevent neurotoxicity have been studied,
but none have shown suﬃcient success to use routinely.
Tables 2 and 3 summarizes the trials, their interventions, and
results.
Glutathione, a tripeptide amino acid, has been shown to
act as an antioxidant and prevent oxaliplatin accumulation
in nerves [54, 55]. A small 52-patient randomized trial of
intravenous reduced dose glutathione given with oxaliplatin
reported that the rate of grade 3 neurotoxicity at 8 weeks
was signiﬁcantly less in the group receiving glutathione (0%4 Journal of Oncology
Table 2: Prevention of oxaliplatin-induced peripheral neuropathy.
Study reference Intervention Results
OPTIMOX1 [33] Continuous FOLFOX-4 versus
intermittent FOLFOX-7
No signiﬁcant reduction in grade 3 neuropathy in the
intermittent arm
CONcePT [34]
Continuous oxaliplatin versus
intermittent oxaliplatin Reduced grade 3 neuropathy in the intermittent arm
C a / M gv e r s u sp l a c e b o N or e d u c t i o ni ng r a d e3 / 4n e u r o p a t h yi nC a / M gg r o u p
Gamelin et al. 2004 [40] Ca and Mg versus historic
control Reduced grade 3 neuropathy in Ca/Mg group
CAIRO2 trial [41] Ca/Mg versus no prevention
treatment N or e d u c t i o ni ng r a d e3 / 4n e u r o p a t h yi nC a / M gg r o u p
N04C7 trial [18] Ca/Mg versus placebo Reduced grade 2 or worse neuropathy in Ca/Mg group
Neuroxa trial (ongoing)
[42]
Ca/Mg versus no prevention
treatment Reduced grade 3 neuropathy in Ca/Mg group
Cascinu et al. 2002 [43] Glutathione versus placebo Reduced grade 3 neuropathy with glutathione
Lin et al. 2006 [44] N-acetylcysteine versus placebo Reduced grades 2–4 neuropathy with N-acetylcysteine
Wang et al. 2007 [45] Glutamine versus no treatment Reduced grade 3 neuropathy with glutamine
Lu et al. 2008 [46] Amifostine versus glutamine Reduced grades 1-2 and 3-4 in amifostine group
Guo et al. 2011 [47] Oral lipoic acid versus placebo No statistical diﬀerence in treatment groups
Von Delius et al. 2007 [48] Carbamazepine versus no
prevention treatment No statistical diﬀerence in treatment groups
Argyriou et al. 2006 [49] Oxcarbazepine versus no
prevention treatment
Reduction in incidence of neuropathy in oxcarbazepine
group
Mitchell et al. 2006 [50] Gabapentin versus no prevention
treatment No reduction in neuropathy
Durand et al. 2003 [51] Venlafaxine versus placebo Reduced grade 3 neuropathy
Cassidy et al. 2008 [16]X a l i p r o d e n v e r s u s p l a c e b o Reduced grade 3 during treatment, but no diﬀerence
after ﬁnishing treatment
Table 3: Treatment of oxaliplatin-induced peripheral neuropathy.
Study Intervention Results
Durand et al. 2003 [51] Venlafaxine versus
placebo
Reduced grade 3
neuropathy
Rao et al. 2008 [52] Lamotrigine versus
placebo
No reduction in
neuropathy
versus 26%) [43]. There was no diﬀerence in chemotherapy
response. N-acetylcysteine, which increases glutathione
blood concentrations, showed promising beneﬁt in prevent-
ing OXIN in a small 14-patient study [44]. Glutamine,
another amino acid, has shown promising preventative
qualitiesinasmallrandomizedtrialoforalsupplementation,
but larger conﬁrmatory trials are required [45]. The free
radical scavenger amifostine was more eﬀective than glu-
tamine in preventing neurotoxicity when given subcuta-
neously before oxaliplatin-based chemotherapy [46]. More
recently, lipoic acid, an antioxidant, was shown to be no
better than placebo in preventing platinum-induced neu-
ropathyinarandomizedtrialofgivingthedrugorallyduring
chemotherapy [47].
Carbamazepine, a widely used antiepileptic drug that
blocks sodium channels, has also been tried as a preventative
measure. However, the drug has a wide range of side eﬀects
and low therapeutic index, and a randomized trial of
the strategy was ineﬀective [48]. Gabapentin was also inef-
fective when tried as a preventative measure in a randomised
trial [50]. Oxcarbazepine, an analogue of carbamazepine,
was eﬀective in a small randomized trial in preventing OXIN
[49], but larger conﬁrmatory trials are required.
Xaliproden is an oral drug that acts through the 5HT1
serotonin receptor and has neurotrophic eﬀects [56]. A large
randomized trial of xaliproden with 649 patients receiving
FOLFOX-4 chemotherapy reported reduced grade 3 neuro-
pathy in patients taking xaliproden (11% versus 17%), but
there was no diﬀerence in the percentage of patients with
complete recovery after ﬁnishing treatment with oxaliplatin
(49 versus 47 percent), and the use of the drug for this indi-
cation has been abandoned [57].
4. Treatment
There are few comparative studies to guide clinicians regard-
ing appropriate treatment of established acute or chronic
OXIN. Venlafaxine, an antidepressant that is a serotonin and
norepinephrine reuptake inhibitor, may be appropriate for
the treatment of acute OXIN [51, 58]. A randomized trial of
venlafaxine in patients with acute OXIN receiving FOLFOX
chemotherapy for adjuvant or palliative treatment of colon
cancer demonstrated a reduction in the proportion of pa-
tients suﬀering from acute OXIN from 31.3% in the placeboJournal of Oncology 5
arm versus 5.3% in the venlafaxine arm (P = 0.03) [58].
Although the trial was small with 54 patients, it also demon-
stratedinasecondaryendpoint thatvenlafaxinewaseﬀective
in reducing the incidence of chronic OXIN that was grade 3
or worse from 33% in the placebo arm to 0% in the ven-
lafaxine arm, suggestive that venlafaxine therapy may also be
useful as a preventative measure. Amitriptyline use resulted
in a nonsigniﬁcant trend to improvement in sensory neuro-
pathy in a small, 44-patient randomized trial of cancer pa-
tients with chemotherapy-induced neuropathy, of whom 11
patients had oxaliplatin-induced pain [59]. However, a nega-
tive randomised trial suggests lamotrigine is ineﬀective as
treatment for chemotherapy-induced neuropathy [52]. Bas-
ed on individual case reports and small nonrandomized ser-
ies, other potential therapeutic options for patients, once
large conﬁrmatory studies are done, include gabapentin [60]
and pregabalin [60, 61].
5. Conclusion
OXIN causessigniﬁcant morbidity and is often the dose-lim-
ited factor in treatment of advanced colon cancer. Signiﬁcant
advancement has been made to understand the acute and
chronic phases of OXIN, but further research is necessary to
develop rational therapeutic options. The current literature
in prevention of OXIN is inadequate to guide clinical deci-
sion making. Larger future studies are needed to further elu-
cidate the most eﬀective strategies of prevention and treat-
ment of OXIN.
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